BEIJING: Gilead Sciences, the US biotech company behind the experimental drug remdesivir, has applied for eight patents surrounding the drug in China, with three of them approved and the other five still pending, an official said.
The drug originally designed to combat Ebola is currently in clinical trials in China to treat Covid-19 and results are expected to be released on April 27, said He Zhimin, the deputy director of the National Intellectual Property Administration, in a press briefing yesterday.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!